Literature DB >> 7607896

[Necrobiotic xanthogranuloma with eye involvement. Overview and case report].

S Hohenleutner1, U Hohenleutner, W Stolz, M Landthaler.   

Abstract

Necrobiotic xanthogranuloma is a rare disease marked by yellowish-brown plaques with destructive growth and a tendency to ulceration, which shows a characteristic histopathological pattern of palisading granuloma with foam cells, Touton's and foreign-body giant cells, bizarre multinuclear giant cells, cholesterol clefts and marked necrobiosis of the connective tissue. Necrobiotic xanthogranuloma is associated with IgG paraproteinaemia, and occasionally with an IgA paraproteinaemia. Ocular symptoms and visceral involvement are common. We report a case of a 53-year-old woman with periorbital necrobiotic xanthogranuloma, ocular involvement and IgG paraproteinaemia, who had undergone argon-laser treatment to no avail following a diagnosis of xanthelasma. Periorbital xanthelasma-like lesions with a tendency to ulceration in combination with unexplained ocular symptoms consisting of keratitis, scleritis, episcleritis or uveitis should suggest the diagnosis of necrobiotic xanthogranuloma, especially if they are associated with paraproteinaemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607896     DOI: 10.1007/s001050050261

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  3 in total

1.  [Disseminated asymptomatic nodules and plaques].

Authors:  C Appelhans; J Wundenberg; F Breuckmann; P Altmeyer; A Kreuter
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

2.  [Long-term course of necrobiotic xanthogranuloma with ocular involvement].

Authors:  S Meyer; M Landthaler; S Hohenleutner
Journal:  Hautarzt       Date:  2006-02       Impact factor: 0.751

3.  [Disseminated necrobiotic xanthogranuloma].

Authors:  M Klingner; G Hansel; J Schönlebe; U Wollina
Journal:  Hautarzt       Date:  2016-11       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.